MYC and prostate carcinoma: Therefore, metabolic pathways (OXPHOS, amino acids, and lipid metabolism), AR signaling, neuroendocrine metabolism, Myc, and epigenetics drive metabolic reprogramming in prostate cancer and PCSCs.